Vancomycin-resistant enterococci (VRE) colonization of high-risk patients in tertiary care Canadian hospitals
- 1 September 1999
- journal article
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 35 (1) , 1-7
- https://doi.org/10.1016/s0732-8893(99)00045-0
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Enterococci and Vancomycin ResistanceClinical Infectious Diseases, 1998
- Antimicrobial Activity of Quinupristin-Dalfopristin (RP 59500, Synercid®) Tested against Over 28,000 Recent Clinical Isolates from 200 Medical Centers in the United States and CanadaDiagnostic Microbiology and Infectious Disease, 1998
- Historical Yearly Usage of VancomycinAntimicrobial Agents and Chemotherapy, 1998
- Gram-positive resistance: challenge for the development of new antibioticsJournal of Antimicrobial Chemotherapy, 1997
- In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristinJournal of Antimicrobial Chemotherapy, 1997
- Provisional interpretive criteria for quinupristin/dalfopristin susceptibility tests.Journal of Antimicrobial Chemotherapy, 1997
- Vancomycin‐Resistant Enterococci (VRE) in Canada – Results of the Canadian Nosocomial Infection Surveillance Program 1996 VRE Point Prevalence Surveillance ProjectCanadian Journal of Infectious Diseases and Medical Microbiology, 1997
- CURRENT PERSPECTIVES ON MULTIDRUG-RESISTANT BACTERIA: Epidemiology and ControlInfectious Disease Clinics of North America, 1996
- Characterization of glycopeptide-resistant enterococci from U.S. hospitalsAntimicrobial Agents and Chemotherapy, 1993
- In Vitro Activity of Ampicillin or Vancomycin Combined with Gentamicin or Streptomycin Against EnterococciAntimicrobial Agents and Chemotherapy, 1973